While effector T cells can transiently express these molecules during activation or prolonged activation, high levels of these molecules are associated with an exhausted T cell phenotype, thereby limiting their tumor lytic potential (106), Since the anti-tumor efficacy of Lm-based vaccines is through induction of potent tumor-specific CD8+ T cells, maintaining their functionality is necessary for an effective immunotherapeutic platform (3). Here, CD8A is linked to neoplasm.